Five GranuFlo Lawsuit Claims Filed in West Virginia, Likely to Join Hundreds in Federal Massachusetts Litigation
Five new NaturaLyte and GranuFlo lawsuit claims alleging injuries caused by a pair of recalled dialysis medications have now been filed in West Virginia, according to court documents.
Filed on November 5th in Charleston, reports indicate that these cases are likely to be removed to the federal dialysis litigation currently underway in the U.S. District Court, District of Massachusetts. Four out of five of the lawsuits were brought on behalf of individuals who allegedly died as a result of receiving GranuFlo and NaturaLyte, two acid concentrates that were recalled in June 2012 for their potential to increase a patients’ risk for strokes, sudden cardiac death, heart attacks, cardiopulmonary arrest, and other life-threatening side effects.
Almost 400 GranuFlo Recall Lawsuits Now Pending in Federal Massachusetts Litigation
These newly-filed cases will join the hundreds of others that have been filed against Fresenius Medical Care, the makers of GranuFlo and NaturaLyte, in a proceeding underway in Massachusetts federal court. An update issued November 18th by the U.S. Judicial Panel on Multidistrict Litigation (JPML) indicates that 393 lawsuits against Fresenius Medical Care are now pending in the U.S. District Court, District of Massachusetts.
These cases similarly allege that Fresenius, who is a leading supplier of dialysis supplies and services in the U.S., failed to adequately warn doctors and patients about the serious side effects associated with its products prior to the recall. They further allege that Fresenius’ Urgent Product Notification, which was issued in March 2012 to alert the general public of heart problems that may stem from GranuFlo and NaturaLyte, was issued too late. In addition to the federal GranuFlo and NaturaLyte lawsuit litigation underway in Massachusetts, a number of claims have been consolidated in proceeding established in Middlesex County Superior Court.
Lawsuits against Fresenius also point to an internal memo sent in November 2011 to physicians operating in its dialysis clinics that warned of 900 deaths that occurred in patients who underwent treatments using GranuFlo or NaturaLyte. Doctors outside the company’s network were not informed of these deaths until March 2012.
Given this information, the New York Times reported last summer that the U.S. Food and Drug Administration (FDA) had begun to investigate whether Fresenius violated federal laws by withholding this vital safety information from the public.
Take Action Against Fresenius. File a GranuFlo Lawsuit Today.
File a NaturaLyte or GranuFlo lawsuit today with the help of an attorney at Bernstein Liebhard LLP. Call the following number for a free and confidential case evaluation: (877) 779-1414.